The neutrophilic serine protease proteinase 3 (PR3) is involved in inflammation and immune response and thus 19 appears as a therapeutic target for a variety of infectious and inflammatory diseases. Here we combined kinetic and molecular 20 docking studies to increase the potency of peptidyl-diphenyl phosphonate PR3 inhibitors. Occupancy of the S1 subsite of PR3 by 21 a nVal residue and of the S4−S5 subsites by a biotinylated Val residue as obtained in biotin-VYDnV P (O-C 6 H 4 -4-Cl) 2 enhanced 22 42 Indeed, there is no specific endogenous inhibitor of human PR3 43 (humPR3) and one of its more potent inhibitors, α-1-44 proteinase inhibitor (α1PI), interacts about 100 times less J. Med. Chem. XXXX, XXX, XXX−XXX cdz00 | ACSJCA | JCA10.0.1465/W Unicode | research.3f (R3.6.i12 HF03:4459 | 2.0 alpha 39) 2017/11/27 07:41:00 | PROD-JCAVA | rq_12999648 | 2/16/2018 12:18:24 | 13 | JCA-DEFAULT 45 rapidly with humPR3 than with humNE. 7 Further, the 46 pathophysiological role of humPR3 is less well understood 47 than that of the related humNE and CG. Its function as 48 autoantigen in granulomatosis with polyangiitis 8−10 and its 49 likely involvement in neutrophil apoptosis 11 makes it different 50 from its closest homologue humNE.
the second-order inhibition constant k obs /[I] toward PR3 by more than 10 times (k obs /[I] = 73000 ± 5000 M −1 s −1 ) as compared 23 to the best phosphonate PR3 inhibitor previously reported. This inhibitor shows no significant inhibitory activity toward human 24 neutrophil elastase and resists proteolytic degradation in sputa from cystic fibrosis patients. It also inhibits macaque PR3 but not 25 the PR3 from rodents and can thus be used for in vivo assays in a primate model of inflammation. 26 ■ INTRODUCTION 27 Polymorphonuclear neutrophil phagocytes are characterized by 28 the presence of abundant intracytoplasmic granules rich in 29 antimicrobial peptides and proteins involved in innate 30 immunity. 1,2 Azurophilic granules also store four neutrophil 31 serine proteases (NSPs): proteinase 3 (PR3), elastase (NE), 32 cathepsin G (CG), and neutrophil serine protease 4 (NSP-4), 33 which are released into the environment in response to 34 inflammatory stimuli. 1,3 An excess of proteases may be released, 35 however, during chronic inflammation which disrupts the 36 protease−protease inhibitor balance and accelerates proteolysis 37 of the extracellular matrix. 4, 5 The administration of exogenous 38 inhibitors targeting these proteases may thus be an excellent 39 therapeutic strategy to fight inflammation. 5, 6 Although the total 40 amount of PR3 in neutrophils is similar to that of NE or CG, its 41 activity is by far less controlled by endogenous inhibitors. 7 (Table 1 ) and significantly improved the K i value of the initial t2 141 noncovalent complex (21 vs 3600 nM) (Table 2) . Accordingly, 142 the substitution of the N-terminal acetyl group by a biotin in 143 the paranitroanilide (pNA) substrate Ac-PYDA-pNA increased t3 144 the specificity constant k cat /K m by ∼6-fold (Table 3) . We 145 employed a computational docking approach to explain how 146 biotin could modulate the interaction between Bt-PYDA P (O-f2 147 C 6 H 4 -Cl) 2 and the active site of PR3 (Figure 2A,B) . The lowest 148 energy binding mode obtained in the docking studies of 2 with 149 humPR3 revealed that the biotin moiety is located in the S5 150 pocket limited by the Lys99, Phe166, Cys168, Arg177, and 151 Ile217 residues ( Figure 2B ). The entrance into this pocket is 152 guarded by the Lys99 side chain with its ε-amino group, 153 creating a hydrogen bonding with the carbonyl oxygen of the 154 Bt-Pro4 amide bond. This interaction would facilitate the 155 correct orientation of both Pro4 and biotin in the S4 and S5 156 binding sites, respectively. The arrangement of Phe166, (Table 1) . The docking 163 model shows that the length of the biotin moiety is optimal for 164 the binding in the S5 pocket, and any spacer between the Pro4 165 and biotin would not improve the interaction. A biotin at P5 Influence of the P4 Residue on the Inhibitory Activity 169 of Bt-Peptidyl P (O-C 6 H 4 -4-Cl) 2 Phosphonate Inhibitors. 170 The computational docking study showed that the P4 residue 171 Pro in 2 was close to solvent accessible hydrophobic Trp218 in 172 PR3 ( Figure 2B ). We replaced the P4 Pro by Val (4), Leu (5), 173 Ile (6), and norleucine (nLeu) (7) to tentatively optimize the 174 interaction with the PR3 hydrophobic patch build by residues 175 Phe166, Ile217, Phe224, and possibly with Trp218. While Leu 176 or Ile at P4 position decreased the inhibitory activity toward 177 PR3, the presence of nLeu or Val improved the inhibitory 178 activity by ∼2 and ∼4 times, respectively (Table 1) . 179 Accordingly, the specificity constant k cat /K m of the pNA 180 substrate Bt-VYDA-pNA was also improved (Table 3) . 181 Whatever the substitution at P4 in phosphonate inhibitors 182 was, the resulting compound retained no significant inhibitory 183 activity toward humNE although this protease also prefers a 184 hydrophobic residue at this position. Because the S4 subsite is 185 composed mainly by side chains of Trp218 and Ile217 and the 186 distinctly hydrophobic area (Phe166, Phe224) span beyond this 187 position, we decided to probe the existence of interactions by 188 substitution nLeu by nLeu(O-Bzl) at P4 in 7 (8). However, this 189 resulted in more than 10 times lower k obs /[I] value (Table 1) . 190 Moreover, the molecular docking model did not confirm the (9) showed similar efficacy toward PR3 (Table 1) . However, 210 Bt-PYDnV P (O-C 6 H 4 -4-Cl) 2 (10) was ∼4.5 times more potent 211 than 2. (Table   219 2). Combining Val at P4 and nVal at P1 in the pNA substrate 220 Bt-VYDnV-pNA also significantly increased the specificity 221 constant toward PR3 (Table 3) . 222 The computational docking approach employed to examine The residues of the catalytic triad H57, D102, and S195 are underlined. The carbon atoms of PR3 and the compounds are shown in white and cyan, respectively. The oxygen, nitrogen, sulfur, and phosphorus atoms are colored in red, blue, yellow, and orange, respectively. D 234 improved flexibility of this region upon enzyme−inhibitor 235 binding. The ε-amino group of Lys99 forms hydrogen bonds 236 with Bt-Val4 amide carbonyl oxygen as well as Asp2 carboxyl 237 group. Additionally, quantum chemical calculations of inter-238 action energy revealed that Lys99 residue contributes the most 239 to binding of Bt-Val4 portion of the inhibitor, as the value of 240 the interaction energy due to the presence of this particular t4 241 residue amounts to −16.6 kcal/mol (Table 4 ). Attracting 242 interactions between Bt-Val4 tail of 11 and PR3 residues were 243 also found for Phe166 and Val216 (−3.8 and −1.6 kcal/mol, 244 respectively). Except for Ile217, Trp218, and Phe215 residues 245 that appear to exert unfavorable influence in terms of Bt-Val4 246 binding, the remaining PR3 residues promote Bt-Val4 binding 247 with the interaction energy not exceeding −1 kcal/mol. It 248 should be pointed out that excessively repulsive interactions 249 associated with some residues probably arise from the lack of 250 quantum chemical refinement of the binding poses obtained 251 from docking simulations, as empirical force field based 252 methods often employed throughout the docking procedures 253 tend to introduce shortened intermolecular contacts. 28 The 254 location of the biotin rings into the S5 binding site prevents 255 recognition of all these compounds by extravidin by Western 256 blotting (WB) under nondenaturating/reducing conditions 257 (not shown). 258 Stability of Bt-VYDnV P (O-C 6 H 4 -4-Cl) 2 (11) in a Bio-259 logical Environment. We then tested the properties of 11 in 260 sputa from patients with cystic fibrosis (CF) and measured 261 humPR3 activities of sputum samples before and after 
a In units of kcal/mol.
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Article DOI: 10.1021/acs.jmedchem.7b01416 J. Med. Chem. XXXX, XXX, XXX−XXX 267 3B), while humNE activity remained unchanged (not shown). 268 Inhibitor 11 was also successfully used to selectively label 269 proteolytically active humPR3 in CF sputum and in a lysate of 270 purified human blood neutrophils ( Figure 3C ). Additionally, 271 we showed that inhibitor 11 preserved full inhibitory activity 272 and resisted degradation when it was mixed with CF sputum 273 for 2 h at 37°C as shown by high performance liquid 274 chromatography (HPLC) ( Figure 3D ). 275 Characterization and Inhibition of Macaque PR3 276 (macPR3) by Phosphonate Inhibitors in Purified Neu-277 trophil Lysates. Protein sequences alignment of humPR3 and 278 macaque PR3 (Macaca fascicularis) shows that they are 86% 279 identical, and they differ by only 28 residues. Their substrate 280 binding site is very similar and critical residues Lys99, Arg143, 281 and Ile217 that confer high selectivity to humPR3 are conserved 282 f4 in macPR3 ( Figure 4A k obs /I = 36480 ± 3350 M −1 s −1 ), but their overall potency was 292 somewhat lesser than that recorded for humPR3 (Table 1 ). The 293 inhibition of macPR3 with 11 is shown in Figure 3C . To further examine binding preferences of 11 against human 295 and macPR3 proteases and interaction energy values between 296 Bt-Val4 fragment of the inhibitor and PR3, binding sites were 297 compared for particular residues representing S5 binding 298 pocket (Table 4 ). Lys99, the most important residue promoting 299 inhibitor binding of humPR3, seems to exert also the largest 300 influence in terms of the analogous interaction with macPR3. 301 However, the corresponding binding energy value is less 302 significant in the case of macPR3−inhibitor complex compared 303 to interaction with humPR3 (−10.0 versus −16.6 kcal/mol; 304 Table 4 ). Another substantial difference in binding energy 305 values concerns repulsive interaction due to the presence of 306 Phe215 residue. Unfavorable interaction characterizing 307 humPR3−inhibitor complex (5.5 kcal/mol) amounts to 24.2 308 kcal/mol in the corresponding macPR3 Phe215−inhibitor 309 complex (Table 4 ). The remaining repulsive interactions 310 associated with Ile217 and Trp218 are retained in the case of 311 macPR3 inhibition despite the substitution of Trp218 by an 312 arginine residue. Interestingly, three out of five substitutions 313 that involve PR3 residues in the vicinity of the Bt-Val4 inhibitor 314 fragment do not seem to modulate binding potency of 11 315 against human and macPR3 homologues. The more substantial 316 changes related to residue substitution accompany the change 317 of Phe166 to leucine and Gly219 to glutamate. However, these 
Article 341 is a means to better understand its biological function, but all 342 physiological inhibitors of humPR3 preferentially target 343 humNE. It is only recently that we and others began to 344 synthesize chemical inhibitors that selectively target the 345 humPR3 active site. 7 The specificity of serine proteases is 346 determined by their substrate binding sites that are located on 347 both sides of the cleaved peptide bond. We used a substrate-348 based approach to develop serpin-like irreversible inhibitor 349 (SerpinB1(STDA/R) and azapeptide (azapro-3), a reversible 350 inhibitor that selectively inhibits PR3. 31 Such inhibitors, 351 however, cannot be used as ABP to visualize active humPR3 352 in biological fluids or in cells and tissues. We recently 353 developed a series of N-terminally biotinylated peptidyl-354 diphenyl phosphonate inhibitors that allow the detection of 355 humPR3 at the cell surface and inside cells. 18 These are 356 transition state analogues, irreversible inhibitors that interact 357 with nonprime subsites of the target serine protease to form 358 "phosphonylated" enzymes. Protease−inhibitor complexes 359 show a remarkable stability due to the similarity of the 360 phosphorus atom with the tetrahedral intermediate formed 361 during peptide bond hydrolysis. Although chemically stable in 362 blood samples, their pharmacological use requires that they 363 interact rapidly with their target protease to be effective at low 364 concentrations. We have further investigated the nonprime 365 specificity of humPR3 to develop more potent di-366 (chlorophenyl)-phosphonate ester inhibitors that could be f5 367 used as molecular probes to control humPR3 activity ( Figure   f5 368 5). 369 We previously showed that the S2/P2 specificity was 370 essential to discriminate between humPR3 and its close 371 homologue humNE. 15 Lys99 in humPR3 is a key residue to 372 explain the preferential accommodation of negatively charged 373 or polar residues at P2. 5,7 Thus, selective humPR3 substrates or 374 peptide sequences selectively cleaved by humPR3 all contain a 375 negatively charged or a polar residue at position P2. 6 376 SerpinB1(STDA/R) and azapro-3 that selectively inhibit 377 humPR3 contain a negatively charged residue (Asp) at P2 378 position. However, humPR3 may accommodate different 379 residues at P1 and P4 as confirmed by molecular modeling 380 studies. The S1 binding pocket of humPR3 is more accessible 381 and spacey than that of humNE and can accommodate not only 382 the Ala or Abu side chain but also methionine, valine, and nVal, 383 which was shown experimentally and by computational 384 docking. In a recent study using single-residue mutant of 385 humPR3 with Arg at position 217 (PR3I217R), we showed that 386 Ile217 located in the neighborhood of the S4 subsite pocket 387 significantly affects the substrate specificity of humPR3. 18 The 388 docking models performed in this study using phosphonate 389 inhibitors indicate also that the solvent accessible surface of the 390 S4 subsite is limited by Trp218 and Ile217 on one side. The 391 latter two residues are most likely responsible for the binding 392 preference toward aliphatic side chains at P4 and Lys99, which 393 is located on the opposite side of the S4 subsite, determines 394 cooperation between S2 and S4 via hydrogen bonding. 395 Targeting the humPR3 active site by specific inhibitors has 471 become evidence as soon as it has been established that it was 472 not a redundant protease mimicking humNE and that its 473 proteolytic activity was poorly controlled by physiological 474 inhibitors. We have optimized here the structure of peptidyl 475 phosphonate inhibitors by coupling molecular modeling studies 476 with kinetic analyses, and we obtained molecular probes to 477 follow the fate and further investigate the function of PR3 both 478 in vitro and in vivo. The potency and selectivity of the 479 inhibitors developed here let us suppose that they are suitable 480 therapeutic tools for fighting inflammatory and/or infectious 481 diseases where the role of humPR3 has been clearly identified 482 or even only suspected. Synthesis of Peptidyl-phosphonate Inhibitors. All reagents 491 and solvents were obtained from commercial sources and were used 492 without purification. 493 All final compounds were purified to >95% purity HPLC system 494 (Jasco LC System, Jasco, Japan) equipped with Supelco Wide Pore C8 495 column (8 mm × 250 mm) and ultraviolet−visible (UV−vis, 226 nm) 496 and fluorescent detectors (excitation 320 nm, emission 450 nm). A 497 linear gradient from 10 to 90% of B within 40 min was applied (A, 498 0.1% TFA in water; B, 80% acetonitrile in A). 499 The nuclear magnetic resonance spectra ( 1 H, 31 P and 13 C) were 500 recorded on either a Bruker Avance DRX-300 (300.13 MHz for 1 H 501 NMR, 121.50 MHz for 31 P NMR), a Bruker Avance 600 MHz (600.58 502 MHz for 1 H NMR, 243.10 MHz for 31 P NMR, and 101.12 MHz for 503 13 C NMR) or Bruker AVANCE III 700 MHz (700.67 MHz for 1 H 504 NMR) spectrometer. Chemical shifts are reported in parts per million 505 (ppm) relative to a tetramethylsilane internal standard. Mass spectra 506 were recorded using a Biflex III MALDI TOF mass spectrometer 507 (Bruker, Germany). The cyano-4-hydroxycinnamic acid (CCA) was 508 used as a matrix. High resolution mass spectra (HRMS) were acquired 509 either on a Waters Acquity Ultra Performance LC, LCT Premier XE, 510 or Bruker micrOTOF-Q II mass spectrometer. 511 Cbz-Protected 1-Aminoalkylphosphonate Diaryl Esters (General 512 Procedure). The first step in the synthesis of the phosphonic 513 analogues of Ala, nVal, and Abu was the preparation of tri(4-514 chlorophenyl)phosphite from 4-chlorophenol and phosphorus tri-515 chloride. 36 Briefly, phosphorus trichloride (10 mmol) was added to 4-516 chlorophenol (30 mmol) dissolved in acetonitrile (50 mL) and the 517 mixture refluxed for 6 h. The volatile elements were removed in a 518 vacuum, and the resulting crude phosphite, a yellow oil, was used 519 directly in an amidoalkylation reaction. It was mixed with benzyl 520 carbamate (12 mmol) and an appropriate aldehyde: acetaldehyde, 521 butyraldehyde, or propionaldehyde (12 mmol) and refluxed in acetic 522 acid for 3 h (Oleksyszyn's method 37 ). 523 Deprotection of Cbz Group (General Procedure). The Cbz 524 protecting group was removed by incubation with 33% hydrobromic 525 acid in acetic acid (2 h). The volatile components were removed under 526 reduced pressure, and the products were crystallized from methanol/ 527 diethyl ether to give target compounds as hydrobromide salts. 528 Benzyl (1-(Bis(4-chlorophenoxy)phosphoryl)ethyl)carbamate (12, 529 Cbz-Ala P (O-C 6 H 4 -4-Cl) 2 ). 12 was prepared using the general method 530 described above and crystallized from methanol to yield a white solid 531 (56% 
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